Published: 6 November 2023
Author(s): Vasileios Lekakis, George V. Papatheodoridis
Issue: May 2024
Section: Review Article

Metabolic dysfunction-associated steatotic liver disease (MASLD) has been the term for non-alcoholic fatty liver disease (NAFLD) since June 2023 and will be used instead of NAFLD throughout this review. MASLD currently represents the most common liver disease worldwide having a global estimated prevalence of 32 % [95 % confidence interval (CI):30–35 %] and a leading cause of liver-related morbidity and mortality [1,2]. MASLD prevalence differs significantly by world region attributed to disparities in obesity rates, genetic and socioeconomic influences.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.